Celera Corporation Publishes Review Article on the KIF6 Gene Variant as a Predictor of Risk of Coronary Heart Disease (CHD) and Reduction in Coronary Events from Statin Therapy

ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) today announced the publication of a review article on the KIF6 gene variant as a predictor of risk of coronary heart disease (CHD) and reduction of CHD events from statin therapy. This review of multiple studies of over 50,000 people included a meta-analysis of 7 prospective studies showing that a variant of the KIF6 gene is strongly associated with increased risk of CHD (P value = 1x10-6). These included the results of genetic studies of 4 landmark prospective, randomized clinical trials, the gold standard for clinical research, in which it was found that statin therapy significantly reduced CHD events in KIF6 719Arg carriers, but not in noncarriers. This review has been published ahead of print in the American Journal of Cardiology, and is currently available on the publication’s website at: http://www.ajconline.org/article/S0002-9149(10)01138-0/abstract.